DXR - Daxor Corporation logo

Daxor Corporation

DXR

Daxor Corporation develops medical instruments focused on blood volume measurement, including the BVA-100 Blood Volume Analyzer and diagnostic kits for heart failure. Its services cater to hospitals and critical care facilities, enhancing patient management.

โš•๏ธ Healthcare NASDAQ Listed 1992 $ USD
$1,000 invested 30 years ago โ†’$1,259today

Score Overview

1 Year
Score
Net Growth17x
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth-76.37%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score7.6
Net Growth7x
Net Trend80%
Net Income Consistencyโ€”
Rev Growth150.53%
Rev Trend60%
Revenue Consistencyโ€”
10 Years
Score
Net Growth200.26%
Net Trend70%
Net Income Consistency
Rev Growth106.76%
Rev Trend60%
Revenue Consistency
20 Years
Score3.8
Net Growth8x
Net Trend60%
Net Income Consistency
Rev Growth-62.53%
Rev Trend45%
Revenue Consistency
30 Years
Score
Net Growth7x
Net Trend53%
Net Income Consistency
Rev Growth-89.29%
Rev Trend50%
Revenue Consistency
All Time
Score
Net Growth169.70%
Net Trend48%
Net Income Consistency
Rev Growth-91.75%
Rev Trend48%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Daxor Corporation has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 30 years of fundamentals. DXR does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-29
$ 11.70โ€”
1 Year2025-09-29
$ 12.96-9.72%
5 Years2021-09-29
$ 11.501.74%
10 Years2016-09-29
$ 7.9247.81%
20 Years2006-09-29
$ 11.353.09%
30 Years1996-09-27
$ 9.2925.93%
All Time1992-03-17
$ 1.766x

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
2025$ 503.42K$ 9M
2024$ 2M$ 536.33K
2023$ 34M$ 280.64K
2022$ 6M$ 5M
2021$ 5M$ 4M$ 710.7K
2020-$ 996.3K-$ 1M$ 617.8K
2019-$ 114.99K-$ 495.7K
2018-$ 918.45K-$ 885.77K
2017-$ 1M-$ 1M$ 1M
2016$ 1M$ 1M$ 2M
2015-$ 7M-$ 9M$ 2M
2014-$ 4M-$ 976.7K
2013-$ 11M-$ 8M
2012-$ 2M$ 1M
2011$ 1M-$ 7M$ 59.63K
2010$ 1M$ 4M$ 57.74K
2009$ 1M$ 5M$ 277.09K
2008$ 1M$ 15M$ 2M
2007$ 1M$ 10M$ 2M
2006$ 1M-$ 785.53K$ 2M
2005$ 1M-$ 1M$ 93K
2004$ 1M-$ 580.27K$ 5.08K
2003$ 3M-$ 1M$ 3.32K
2002$ 2M-$ 193.85K$ 13.04K
2001$ 758.37K$ 299.36K$ 431.95K
2000$ 745.79K-$ 55.19K$ 18.44K
1999$ 575.38K-$ 97.15K$ 67.78K
1998$ 300K-$ 400K$ 100K
1997$ 500K-$ 200K$ 100K
1996$ 2M-$ 100K$ 100K
1995$ 4M$ 1M$ 100K
1994$ 4M$ 1M$ 100K
1993$ 4M$ 2M$ 300K
IPO1992$ 6M$ 3M$ 200K
DXR - Daxor Corporation logo

Daxor Corporation fundamental performance

Between 2020 and 2025, revenue went from -$ 996.3K to $ 503.42K and net income went from -$ 1M to $ 9M. Revenue increased in 3 of those 5 years; net income in 4.

Between 2015 and 2025, revenue went from -$ 7M to $ 503.42K and net income went from -$ 9M to $ 9M. Revenue increased in 6 of those 10 years; net income in 7.

Daxor Corporation currently holds a 20-year HDB Score of 3.8 out of 10. How the HDB Score is calculated.

Membership

Explore DXR with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,814 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies